Depth of response to induction therapy is likely not sufficient to identify patients who can defer autologous stem cell transplantation (ASCT) in multiple myeloma, a new study finds. Patients with certain characteristics may have good outcomes with deferred ASCT, but the study was too small to make firm conclusions. “The benefit of ASCT is related ...
Induction therapy response can’t stratify MM patients away from ASCT
By Dave Levitan
18 Mar 2021